the third-line rescue therapy with P-CAB for H. pylori infection

the third-line rescue therapy with P-CAB for H. pylori infection - the third-line rescue therapy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029686

Enrollment

100

Registered

2017-10-24

Start date

2015-03-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

vonoprazan 20mg X2/day, amoxicillin500mg X4 (or metronidazole 250mg X2)/day, sitafloxacin100mg X2/day for 1 week

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: the patients with failure of first and second-line eradication treatments for H. pylori infection, or adverse reactions of these treatments.

Exclusion criteria

Exclusion criteria: patients with severe liver diseases, patients taking atazanavir sulfate, and so on.

Design outcomes

Primary

Measure	Time frame
the eradication rate of the third-line rescue therapy	—

Countries

Japan

Contacts

Public ContactHiroyuki Suto

University of Fukui Hospital Department of Gastroenterology

hrykstu@u-fukui.ac.jp0776-61-8351

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026